SIGNIFICANT ACCOUNTING POLICIES (Additional Information) (Details) $ / shares in Units, $ in Millions	1 Months Ended		12 Months Ended
	May 31, 2023 USD ($)	Oct. 31, 2015	Dec. 31, 2024 USD ($) agreement item $ / shares	Dec. 31, 2023 USD ($) $ / shares	Sep. 30, 2024	Aug. 25, 2021
SIGNIFICANT ACCOUNTING POLICIES
Number of global licensing and supply agreements | agreement			2
Amount of milestone payment received	$ 20.0
Accounts receivables write-off			$ 0.0	$ 0.0
Accounts receivables recoveries			$ 0.0	$ 0.0
Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares			$ 0.001	$ 0.001
2024 Notes
SIGNIFICANT ACCOUNTING POLICIES
Interest rate (as a percent)					7.50%	7.50%
Amended Pfizer Agreement | Protalix Bio Therapeutics Incorporation | Brazil
SIGNIFICANT ACCOUNTING POLICIES
Collaborative arrangement revenues and expenses sharing percentage		100.00%
Chiesi Agreements
SIGNIFICANT ACCOUNTING POLICIES
Amount of milestone payment received				$ 20.0
Performance obligation number | item			2